Helius Medical Technologies Inc (NASDAQ:HSDT) does about 813.30K shares in volume on a normal day but saw 5651906 shares change hands in the recent trading day. The company now has a market cap of 0.46M USD. Its current market price is $0.87, marking a decrease of -20.64% compared to the previous close of $1.09. The 52 week high reached by this stock is $24.00 whilst the lowest price level in 52 weeks is $0.80.
The consensus objective for the share price is $60.00, suggesting that the stock has a potential upside of 98.55% over the period.
FactSet Research has provided data showing that 3 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 3 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on March 24, 2021 when Noble Capital Markets initiated the stock to “Outperform” and issued a price target of $20.
The current price level is -75.98%, -79.77%, and -88.99% away from its SMA20, SMA50, and SMA200 respectively, with the HSDT price moving above the 50-day SMA on current market day. Helius Medical Technologies Inc (HSDT) stock is down -76.33% over the week and -79.88% over the past month. Its price is -91.40% year-to-date and -95.31% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at 0 and 0 for whole year. Expected sales for next quarter are $140k, which analysts say will come at $510k for the current fiscal year and next year at $893k. In addition, estimates put the company’s current quarterly revenue at an average of $110k.
To reach the target analysts have set, the stock logically needs to grow 98.55 percent from here.
Outstanding shares total 0.53M with insiders holding 5.75% of the shares and institutional holders owning 0.50% of the company’s common stock. The company has a return on investment of -1020.63% and return on equity of -800.00%. The beta has a value of 1.11. Price to book ratio is 0.28 and price to sales ratio is 1.07.
